# Study of SKY-0515 for Safety, Efficacy, and Pharmacodynamics in Participants With Huntington's Disease

> **NCT06873334** · PHASE2,PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Skyhawk Therapeutics, Inc.** · enrollment: 120 (estimated)

## Conditions studied

- Huntington Disease
- Huntingtons Disease

## Interventions

- **DRUG:** SKY-0515
- **DRUG:** SKY-0515 Placebo

## Key facts

- **NCT ID:** NCT06873334
- **Lead sponsor:** Skyhawk Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2025-05-27
- **Primary completion:** 2027-05
- **Final completion:** 2027-12
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2026-05-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06873334

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06873334, "Study of SKY-0515 for Safety, Efficacy, and Pharmacodynamics in Participants With Huntington's Disease". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT06873334. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*